Innovent Biologics of Suzhou released data at the ASCO meeting for four trials of its China-approved anti-PD-1 antibody, Tyvyt (sintilimab):
• In a Phase II trial of 96 patients with relapsed/refractory classical Hodgkin's lymphoma, Tyvyt produced an objective response rate of 85.4% and a complete response in 29.2% of the patients;
• In a Phase Ib trial of Tyvyt and CAPOX in 20 patients with gastric cancer, objective response rate was 85.0% and disease control rate 100%;
• In patients with resectable squamous non-small cell lung cancer, eight of nine patients with > 30% decrease in standardized uptake values in PET/CT scans had a major pathologic response while those with ≤ 30% decrease in SUV did not achieve MPR.
• Genomic profiling of baseline circulating tumor DNA in Hodgkin's lymphoma patients revealed a potential ctDNA biomarker for Tyvyt.
The Hodgkin's lymphoma trial was the basis for China approval of Tyvyt. More details....
Stock Symbol: (HK: 01801)
Share this with colleagues:
Original Article: Innovent Reports Data on Four China Trials of Approved PD-1 Drug